There were no initial public offerings in the past week, but recent IPO performance continues to trend up. The 24 IPOs in 2015 now average +18%, including +5% after the first day, its highest point this year. A few highlights from February 2015: ...read more
This past week, the set of small health IPOs that had been languishing on the IPO calendar either postponed or went public. • Two small health IPOs raised a...read more
Check-Cap, which is developing an ingestible imaging capsule to detect colorectal cancer, raised $12 million by offering 2 million units at $6, the low end of the range of $6 to $8.
The company commands a fully diluted market value of $61 million, less than...read more
Twelve deals are on the calendar to raise $1.2 billion, which would make it the year's biggest week for IPOs by proceeds and count. However, those numbers could decline...read more
US IPO Weekly Recap: No IPOs in final week of a challenging February
There were no initial public offerings in the past week, but recent IPO performance continues to trend up. The 24 IPOs in 2015 now average +18%, including +5% after the first day, its highest point this year. A few highlights from February 2015: ...read more
US IPO Weekly Recap: Health IPOs go public or postpone ahead of a busy March
This past week, the set of small health IPOs that had been languishing on the IPO calendar either postponed or went public. • Two small health IPOs raised a...read more
Gulp: Imaging capsule maker Check-Cap prices IPO at $6, the low end of the range
Check-Cap, which is developing an ingestible imaging capsule to detect colorectal cancer, raised $12 million by offering 2 million units at $6, the low end of the range of $6 to $8. The company commands a fully diluted market value of $61 million, less than...read more
Week ahead: 12 IPOs feature health care, holdovers and a $500 million health tech IPO
Twelve deals are on the calendar to raise $1.2 billion, which would make it the year's biggest week for IPOs by proceeds and count. However, those numbers could decline...read more